[ 68 Ga]Ga-DO3A-Tuna-2 has been extensively validated as a marker for GCGR occupancy in liver of non-human primate by PET 8
Most researchers still underestimate how much receptor dynamics matter
five milligrams every week
Ben Rome, a health policy researcher at Brigham and Women's Hospital in Boston
Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade
Description Tirzepatide is a research-grade dual incretin agonist supplied in lyophilised form for laboratory use
